Freedom of Information Request: Our Reference CTMUHB_330_26

You asked:

I am writing under the Freedom of Information Act 2000 to request information held by your organisation regarding **Type 1 diabetes testing**. Please complete this form with the information you have available.

Q1. Do you provide autoantibody testing for diagnosis of Type 1 diabetes?

Answer: Yes.

Q1a. If yes, please indicate which assays are available either onsite or via referral to another laboratory:

- GAD
- IA-2
- ZnT8
- IAA

Answer: GAD, IA-2 and ZnT8.

Q1b. Does your organisation receive requests for Type 1 diabetes autoantibody testing in individuals without clinically diagnosed diabetes (e.g. screening of at-risk relatives or other asymptomatic individuals)?

No

Q1c. Please provide the number of unique patients tested clinically for the following autoantibodies during:

- Calendar year 2025
- January–March 2026

Please exclude research-only testing where identifiable.

Please provide separate figures for:

- onsite testing - **No Onsite testing takes place.**
- outsourced/referred testing - **All request's are outsourced.**

If exact patient numbers are not available, please provide the closest available measure (e.g. request numbers or assay volumes) and specify the metric used.
Answer table:

		Patients Tested Onsite	**Outside Lab**
2025 (Calendar Year)	**GAD only**	**N/A**	**97**
	Combination of any of GAD, IA-2 and/or ZnT8	**N/A**	***197**
	IAA only (if available)	**N/A**	**0**

1st quarter 2026 (January – March)	**GAD only**	**N/A**	**0**
	Combination of any of GAD, IA-2 and/or ZnT8	**N/A**	****52**
	IAA only (if available)	**N/A**	**0**

***In 2025, 197 patients had all x3 tests shown, 97 had GAD only requests, and 21 patients had permutations thereof. No patients with ONLY IA2 requested.**

****In 2026, <u>all</u> patients had all 3 antibodies measured – the referral Laboratory at Exeter provides a x3 test fixed panel (GAD, IA2 and ZnT8).**

Q1d. If an external laboratory is used, please provide:

- laboratory/provider name
- location

Answer:

- **Prior to 9th June 2025: Oxford and Sheffield laboratories.**
- **From 9th June 2025 to 28th February 2026: Royal Devon & Exeter NHS Foundation Trust, Barrack Road, Exeter. EX2 5DW.**
- **From 1st March 2026: refer to Cardiff (University Hospital of Wales).**

Q2a. If readily available, please provide the number of unique patients in 2025 and Jan–Mar 2026 who tested positive for:

i) one autoantibody

ii) two or more autoantibodies

Please exclude research-only testing where possible.

Answer:

Count of MRN	**Year**		
# of Abs positive	**2025**	**2026**	**Total**
0	**270**	**34**	**304**
1	**19**	**10**	**29**
2	**15**	******	**18**
3	**10**	**5**	**15**

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q2b. Of the unique patients who tested positive, how many were referred through an early stage/asymptomatic screening programme?

Answer: We can confirm that the Health Board does not centrally record this information.

Q3. Please provide the average turnaround time over the last 12 months for Type 1 diabetes autoantibody testing:

- onsite testing
- referred testing (if applicable)

Answer:

- **onsite testing – N/A.**
- **referred testing (if applicable) - 30.4 days.**